Teva price target raised to $28 from $26 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares. After Phase 2 duvakitug data surpassed expectations, the firm continues to see meaningful further upside on the stock despite the already strong performance, the analyst tells investors in a research note. UBS believes Teva is still an under-owned name among Long-only, which UBS expects can change in 2025 as brand transition accelerates and the company de-leverages.